Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by Looking4Doubleson May 28, 2020 10:45am
165 Views
Post# 31082612

RE:RE:Word about Beetlebung Pharma

RE:RE:Word about Beetlebung Pharma NewInvestor68 - I can appreciate your confusion.

First off, you need to recognize that their is a constant bashing/shorting presence on the stock board and they continue to spread disinformation in support of their shorting and trading activities.

MiSdyngNasty, Penny, Theknocker, etc.. are all the same buffoon which has an agenda polar opposite of ours.  This "blob" or entity has posted under about 100 different screen names with the same approach, comments and lies. "IT" tried to short this company right when the stellar GVHD testing results came out and then doubled down on his position last August.  Bottom line, . . "IT' has been losing money ever since and is trying to "TALK" the price of the stock down so "IT" can cover it's positions.

Ed rose is another clown doing similar things.  Don't listen to them - they haven't been right about anything significant.

As for thinking these companies are all the same people, etc.. that's just the "narrative" coming out of the bashers to scare people

MY TAKE is that what you are looking at is 3 "small" companies that believe in medical cannibus technology coming out of Israel, which has been leading the scientific community in this area..

Beetlebung can be looked at as pure scientists who are trying to "create" new technologies. That's also the reason their expertise is being used on patents, etc.. 

Salzman and Kalytera are similar in that they are trying to take early technology to market. (ie get ideas/therapies through phase 1,2 and 3 testing.  When the cannibus industry got hammered last year, all of the smaller companies had to start thinking creatively in how to acquire funding for their efforts. 

Kalytera thought our GVHD testing results were impressive enough that we could get a lucrative and "fair" deal with major pharma, however, big pharma has the money and in this kind of market appear to be content on watching the smaller fish use up their money, because they know it will be cheaer to acquire them later. 

Salzman saw expansion into R-107 a way to get unique government contracts and to develop a relationship which could be leveraged on other therapies, etc..  Kalytera has finally recognized that until they find a "fair" partnership or buyout of their GVHD they have to move forward in other ways. 

Then Trump announced his "Operation Warp Speed"  It is a massive effort to expedite solutions for COVID, similar to when the U.S. effort on the development of the first nuclear weapon to end a world war (ie The Manhattan Project)

In this effort, they have already clearly stated that they intend to throw billions of dollars at HUNDREDS of companies in a collaborative attempt to pursue the best technologies out there for vaccine development and treatments for the conditions killing people right now,  That's when Kalytera saw the potential for partnering with Salzman in pursuit of these lucrative contracts.  Salzman already has an initial contract and key therapy (R-107) which is being developed in case of a chlorine attack on U.S. soldiers, similar to what is currently happening to opposition forces in Syria - so they have an income stream.

Kalytera has GVHD and their pain mgmt therapy which look promising, which have more "financial upside" that what Salzman has, so there is a natural synergy there between 2 small companies wanting to grow and become more financially "independent" of big pharma.

While I said in the Fall that I expected someone like GW Pharma to buy our GVHD, I personally think they are trying to squeeze the stock price and buy it on the cheap with a heavy handed approach to Kalytera negotiations.  I am therefore hoping that both Kaltera and Salzman therapies can obtain a government contract which develops cash flow for us and that our GVHD doesn't need to be sold.  That's the holy grail in my mind. (ie  If successful, they could be a direct competitor to GW Pharma)

Any small biotech company is a risk and you should have a diversified portfolio of such companies, but I personally see a LOT of potential in what these companies have and obviously those shorting the stock do as well - As that activity is now rapicly dwindling over the last month.  We will continue to see attacks on the stock price in a veiled attempt to scare people out of their positions, like we saw in the U.S. the other day, but . .I think the shares are now held in pretty strong hands and with people who are investing for the future and not for the next 90 days.

I hope this and the links below give you a better sense of what the situation is about:

Early relationship with Bettlebung


Why Salzman's contract looks solid -chlorine gas

Trumps Operation Warp Speed


The latter is what is driving up a lot of stocks right now knowing that any successful effort will address vaccines, short-term treatments for this virus and future virus mutations, production facilities, world class labs (which Salzman does have, which could be another revenue source in the right arrangement), etc..

I am intrigued - You have to do your own due diligence and make up your own mind.  Bio-techs are NOT for the faint of heart.  Good luck !
<< Previous
Bullboard Posts
Next >>